In patients with atrial fibrillation undergoing PCI, antithrombotic regimens involving a vitamin K antagonist (VKA) plus dual antiplatelet therapy (DAPT) should be avoided, whereas use of a non-VKA ...
With their first update in 5 years, the European Society of Cardiology (ESC) guidelines for non-ST-segment elevation acute coronary syndromes have incorporated several new concepts plus rethinks ...
Amsterdam, Netherlands – 27 Aug 2023: Switching vitamin K antagonist (VKA) treatment to a non-vitamin K antagonist oral anticoagulant (NOAC) in frail elderly patients with atrial fibrillation is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback